**BKIT** Is My New Groundbreaking Pharma Alert!! Start your research NOW!

January 16, 2017, By smallcapfirm,

New Trade Idea:

Blake Insomnia Therapeutics, Inc. (OTCQB: BKIT)

Research Report: http://breakawaystocks.com/bkit/index.html
Friday’s Closing PPS: $1.239

I hope you enjoyed your extended holiday weekend! Let’s celebrate Martin Luther King Day and all of the many wonderful things that he stood for. Honor him for being the great man that he was!

Now let’s jump right into my full report…

… BKIT is a +$1.00 trade opportunity that has been on a serious breakout since January 9th.

Since January 9th, BKIT has steadily climbed from a low of $0.87 to a high of $1.24! That’s a REAL +42% increase in price per share in just 5 trading sessions!

BKIT was trading as high as $1.55 back in September 2016. A run back to just $1.55 from Friday’s close would represent a REAL +25% move up!

In fact; BKIT currently has a 14-day RSI of just 57! That means there is still plenty of bullish potential ahead for shares of BKIT before we even start to see that overbought RSI of 70!

(BKIT) has immense upside potential right now. Start your research on BKIT while the chart is hot.

BKIT is a solid insomnia pharmaceutical play that is loaded with substantial gain potential for the short-term.

Check out the BREAKOUT CHART on BKIT here…


The chart is so sick right now! Investor Interest has been increasing heavily day by day for the past week. With the 14-day RSI just being at 57; Traders could still be witness to substantial gains before BKIT becomes overbought!

Remember to always do your own research and due diligence and that I’m not a licensed financial advisor.

On January 9th, BKIT ran from a low of $0.87 and hit a high of $1.24 per share on January 13th. 

Did you read what I just wrote? Traders got a REAL CHANCE to capture REAL GAINS of up to +42% in just 5 days!

More Short-Term Indicators:

Exponential Moving Average (EMA) Analysis: VERY BULLISH

Moving Average Convergence Divergence (MACD) Analysis: VERY BULLISH

Fibonacci Analysis: BULLISH

Low Analysis: VERY BULLISH

7 Day Average Directional Indicator: GREEN

10 – 8 Day Moving Average Hilo Channel: GREEN

20 Day Moving Average Vs Price: GREEN

BKIT Company Profile

Blake Insomnia Therapeutics, Inc. is a New York-based pharmaceutical company devoted to improving nighttime and daytime quality of life for people with insomnia. Their patent-pending compound, Zleepax™ (ZLX-1), has demonstrated efficacy without causing side effects identified as the No. 1 problem with current sleep medication. Blake Insomnia completed its reverse merger into NASDAQ OTC in second half of 2015.

Company Website:


About Zleepax

Stress is one of the most common causes of insomnia. However, the relationship between insomnia and stress is complex—with the one often causing or exacerbating the other. A divorce or financial troubles, for example, can cause stress that leads to transient insomnia. This, in turn, can make the person less able to cope during the day, creating further stress. In a vicious circle, the further stress can eventually lead to intermittent or even chronic insomnia, where many patients name stress symptoms such as a pounding heart as what keep them awake at night.

Where traditional hypnotics “force” people to sleep by depressing the central nervous system, ZleepaxTM (ZLX-1) acts by diminishing the physical symptoms of stress that keep people awake at night.

The First Sleep Aid Using Beta Blockers

ZleepaxTM is the first sleep aid with beta blockers as the major active agent.

First generation beta blockers inhibited natural melatonin secretion and had a negative impact on sleep. Recent publications have shown that certain third-generation beta blockers actually improve quality of sleep for patients with mild hypertension.
These third-generation beta blockers has been widely used to treat hypertension since the early 1990s, is well tolerated in chronic use, has an attractive side-effect profile, and should thus perform excellently applied as a sleep enhancer. Their patent application cover the use of beta blockers such as Nebivolol—alone or in combination with other anti-insomnia drugs—for the treatment of stress-related insomnia.

No More Residual Daytime Sedation

According to patients, the No. 1 problem with traditional sleeping pills is residual daytime sedation. The potential for tolerance build-up and addiction are also major perceived disadvantages. Based on beta blockers, ZleepaxTM dramatically reduces these and many other unwanted side effects. This means that, in stark contrast to existing hypnotics, ZleepaxTM should be able to give many patients a better night’s sleep with fewer of the side effects they do not want.



With a scorching chart and a revolutionary pharmaceutical sleeping aid, BKIT may have just started breaking out.

Start your research and due diligence on BKIT now.

P.S. – My track record has been seriously awesome! Just take a look at some of my biggest verified winning trade ideas below:

My Top Trade Alerts

9/1/16 – (SMCE) Ran From .0248 to .035 = +41pct

9/6/16 – (DCLT) Ran From .0028 to .013 = +364pct

9/13/16 – (FLCR) Ran From .0016 to .0065 = +306pct

9/20/16 – (QPRC) Ran From .0022 to .006 = +172pct

9/23/16 – (BLGA) Ran From .0079 to .0155 = +96pct

9/27/16 – (PSNX) Ran From .0089 to .014 = +57pct

9/30/16 – (CORMF) Ran From .4601 to .558 = +21pct

10/04/16 – (AOXY) Ran From .05 to .11 = +120pct

10/07/16 – (ELRN) Ran From .01 to .0425 = +325pct

10/10/16 – (UNDT) Ran From .02 to .145 = +625pct

10/13/16 – (PLLX) Ran From .0388 to .1529 = +294pct

10/18/16 – (ABBY) Ran From .004 to .01534 = +283pct

10/21/16 – (EMAV) Ran From .005 to .0606 = +1112pct

10/25/16 – (ACNV) Ran From .007 to .018 = +157pct

10/27/16 – (NSEH) Ran From .012 to .0299 = +149pct

11/04/16 – (JFIL) Ran From .014 to .0375 = +167pct

11/09/16 – (CGYG) Ran From .03 to .06 = +100pct

11/18/16 – (DTST) Ran From .05995 to .13 = +116pct

11/28/16 – (IEGH) Ran From 5.00 to 5.95 = +19pct

12/02/16 – (KSIX) Ran From .36 to .48 = +33pct

12/06/16 – (STLT) Ran From .58 to .80 = +37pct

12/21/16 – (EMAV) Ran From .0065 to .024 = +269pct

12/22/16 – (ECEZ) Ran From .007 to .0101 = +44pct

12/27/16 – (AEXE) Ran From .0145 to .027 = +86pct

1/10/17 – (KDRH) Ran From .0169 to .076 = +349pct

These Percentage Runs Are Based From The Open To HOD



Make sure to always do your own research and due diligence on any day and swing trade alert I bring to your attention. I am not a licensed financial advisor.



















Additional Sources:















































Read Full Disclaimer

Also always remember that every single alert I send is very volatile and risky. Any one of them could turn into a big loser. In my personal opinion, no matter how much potential any company has, 99pct of the time all that matters is how it trades. If a company doesn’t trade well, nothing else matters. Don’t believe the hype. Be sure to use a tight stop, book gains quickly on these volatile trades, never let any one trade move too far against you, watch out for gaps, make sure the company is trading in a healthy way before you enter, and monitor it closely to make sure momentum is positive. It’s always safest to book gains quickly, even on alerts with long-term potential. (Amateur biased unlicensed opinions)

Pursuant to an agreement between SmallCapFirm and Sierra Publishing Inc. (a non affiliated 3rd party), SmallCapFirm has been hired for a period beginning on 1/16/17 and ending on 1/17/17 to publicly disseminate information about (BKIT) via Website, Email and SMS. We have been paid five thousand USD via bank wire transfer. We expect to receive another six thousand USD (eleven thousand USD total) by 1/27/17 and will update this disclaimer once it is received. We own zero shares of (BKIT).​​​​​​​​​​​​​​

SmallCapFirm’s full disclaimer is to be read and fully understood before using SmallCapFirm’s website, or joining SmallCapFirm’s email or text list. By viewing SmallCapFirm’s website and/or reading SmallCapFirm’s email or text newsletter you are agreeing to SmallCapFirm’s full disclaimer which can be read at:



Leave a Reply

Your email address will not be published. Required fields are marked *